Norelgestromin

Summary

Norelgestromin (CHEMBL1200807) is an approved small molecule; indicated across 3 conditions including hiv infectious disease.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• Indications: 3 conditions
• Clinical trials: 10
• Chemistry: 327.5 Da · C21H29NO2

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1200807
Name	Norelgestromin
Type	Small molecule
Max phase	4
FDA approved	no
PubChem CID	9568628
Molecular formula	C21H29NO2
Molecular weight	327.5
InChIKey	ISHXLNHNDMZNMC-VTKCIJPMSA-N

SMILES: CC[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@]2(C#C)O)CCC4=C/C(=N/O)/CC[C@H]34

IUPAC name: (3E,8R,9S,10R,13S,14S,17R)-13-ethyl-17-ethynyl-3-hydroxyimino-1,2,6,7,8,9,10,11,12,14,15,16-dodecahydrocyclopenta[a]phenanthren-17-ol

Also known as: Deacetylnorgestimate, Norelgestromin, Norelgestromin component of xulane, Norelgestromina, Norelgestromine, RWJ-10553, NORELGESTROMIN, SID144206200, NORGESTIMATE METABOLITE NORELGESTROMIN, norelgestromin, Norgestimate metabolite Norelgestromin

Patent coverage: 72 distinct patent families (145 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 1 (assay-derived). Sample: Nuclear receptor subfamily 1 group I member 2.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

3 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
HIV infectious disease	2	MONDO:0005109	EFO:0000764

2 further indication records had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 10.

Phase distribution

Phase	Trials
PHASE3	4
PHASE1	3
PHASE4	1
PHASE2	1
Not specified	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT00261482	PHASE4	COMPLETED	Evaluation of Women’s Experience With EVRA (Norelgestromin + Ethinyl Estradiol) Transdermal Contraceptive Patch Compared With Previous Methods of Contraception.
NCT00236769	PHASE3	COMPLETED	A Study of Efficacy and Safety With the Transdermal Contraceptive System.
NCT00236782	PHASE3	COMPLETED	A Study of Efficacy and Safety With the Transdermal Contraceptive System Versus Mercilon.
NCT00236795	PHASE3	COMPLETED	A Study of Efficacy and Safety With the Transdermal Contraceptive System Versus Triphasil.
NCT00984789	PHASE3	COMPLETED	Birth Control Patch Study
NCT00320580	PHASE2	COMPLETED	An Open-Label Study to Compare the Bleeding Profile of Norelgestromin/Ethinyl Estradiol in an Extended Regimen to Norelgestromin/Ethinyl Estradiol Given in a Traditional Regimen
NCT00254865	PHASE1	COMPLETED	A Comparative Pharmacokinetic Study of ORTHO EVRA (a Transdermal Contraceptive Patch) and CILEST (an Oral Contraceptive) in Healthy Female Volunteers
NCT00258063	PHASE1	COMPLETED	A Study to Evaluate the Exposure of Norelgestromin and Ethinyl Estradiol From Commercial Lots of EVRA (a Transdermal Contraceptive Patch Manufactured by LOHMANN Therapie-Systeme) and CILEST (an Oral Contraceptive)
NCT00775086	PHASE1	COMPLETED	Bioequivalence Study of Patches With Different Equilibration Profiles
NCT00554632	Not specified	COMPLETED	Birth Control Pill vs Birth Control Patch Study

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).